We work at the convergence of science, medicine, and engineering to reinvent the process of drug discovery and treatment.
The Harvard Program in Therapeutic Science (HiTS) is an academic research and education program that advances the fundamental science underlying human diseases and drug discovery in order to improve patient care.
Our faculty, trainees, and staff study disease using innovative approaches that fuse laboratory investigation, clinical research, and computer science to accelerate the invention of the life-saving medicines and precision diagnostics that are needed to optimally treat individual patients.
HiTS brings together two approaches:
The Laboratory of Systems Pharmacology makes it possible to study the changes that promote disease and the ways in which therapeutic drugs function at the molecular level.
The Center for Regulatory Science focuses on evaluating drugs in clinical trials and balancing the benefits and risks of new medicines.
Explore HiTS Research
News, Events, & Updates
Regulatory Science Forum
“Opportunities for Large Language Models in Regulatory Science“
Dr. Tim Miller, Computational Health Informatics Program (CHIP), Boston Children’s Hospital
Tuesday, September 17th, 12:00pm ET
Twitter @Harvard_Lab
Out yesterday from Baker, Sorger, and colleagues, comes CyLinter--quality control software for high-plex tissue profiling. https://www.nature.com/articles/s41592-024-02328-0?utm_source=twitter&utm_medium=social&utm_campaign=nmeth
Caitlin Mills is the Director of Preclinical Pharmacology in the Laboratory of Systems Pharmacology at Harvard Medical School. We spoke to Caitlin at @ELRIG_UK Drug Discovery about a cell staining and fixation technique for drug screening >>> https://hubs.ly/Q02WsRjp0
This will be a terrific meeting, breaking new ground in matching the right cancer patient to the right drug, the promise of precision oncology.
🎉🚨Exciting News. Congratulations to our colleagues:
Gurkan Mollaoglu
Alexander Tepper
Chiara Falcomatà @ChiaraFalcomata
Alessia Baccarini @alessiabaccari4
Brian D. Brown @Brown_lab1
on identifying IL-4 signaling as a target to enhance ovarian cancer response to…
📰PAPER @CellCellPress from IGI Director Brian Brown shows how ovarian cancers evolve local neighborhood control and use IL-4 to resist anti-PD-1 immunotherapy. The findings support a key role for type 2 immunity in cancer and the possibility of drugging this pathway for therapy.